A broad dosage range does not, by itself, answer the patent enablement question. The specification must teach a skilled person how to carry out the claimed invention without undue experimentation.
In Wyeth LLC v. AstraZeneca Pharmaceuticals LP, the patents concerned treating drug-resistant non-small-cell lung cancer with irreversible EGFR inhibitors. A jury awarded Wyeth $107.5 million, but the district court held the asserted claims invalid for lack of enablement. The Federal Circuit affirmed.
The dispute centered on “unit dosage.”
The claims required daily dosing calculated to produce a therapeutic effect in a patient, not simply killing cancer cells in laboratory tests. That distinction mattered.
The specification projected total daily doses of 1 to 1,000 mg, preferably 2 to 500 mg. But it did not explain how to translate laboratory results into suitable patient dosing. Evidence also showed that therapeutically effective levels for two disclosed compounds exceeded tolerated human doses.
The court did not require FDA approval or actual clinical data. The problem was the missing guidance needed to determine workable daily dosages across the claimed compounds without undue experimentation.
Practical takeaway: for pharmaceutical and biotech portfolios, treatment-claim breadth should match the technical guidance in the application. Explain how the disclosed information supports the claimed treatment, and distinguish established findings from projected results. Broad ranges should not be expected to replace the teaching needed to use them.
Federal Circuit opinion:
Wyeth LLC v. AstraZeneca Pharmaceuticals LP
Decided July 9, 2026.
https://www.cafc.uscourts.gov/opinions-orders/24-2325.OPINION.7-9-2026_2720804.pdf







